A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (NCT06393712)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Los Angeles, California
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (57 Sites)
Showing the first 25 of 57 sites.
- Clinical Trial Site — Los Angeles, California
- Clinical Trial Site — Orange, California
- Clinical Trial Site — Palo Alto, California
- Clinical Trial Site — Sacramento, California
- Clinical Trial Site — San Francisco, California
- Clinical Trial Site — Aurora, Colorado
- Clinical Trial Site — New Haven, Connecticut
- Clinical Trial Site — Gainesville, Florida
- Clinical Trial Site — Jacksonville, Florida
- Clinical Trial Site — Maitland, Florida
- Clinical Trial Site — Naples, Florida
- Clinical Trial Site — Chicago, Illinois
- Clinical Trial Site — Lexington, Kentucky
- Clinical Trial Site — New Orleans, Louisiana
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Plymouth, Massachusetts
- Clinical Trial Site — Rochester, Minnesota
- Clinical Trial Site — St Louis, Missouri
- Clinical Trial Site — Hackensack, New Jersey
- Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
- Clinical Trial Site — Durham, North Carolina
- Clinical Trial Site — Canton, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cerebral Amyloid Angiopathy
- A Study of AMDX-2011P in Participants With CAA — Phoenix, Arizona
Explore by condition: All Cerebral Amyloid Angiopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.